Travere Therapeutics Announces Full FDA Approval of FILSPARI® (sparsentan), the First and Only Approved Medicine for FSGS View Full Press Release Travere Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)